AptameX Production and Commercialization Update
28 avr. 2022 08h15 HE
|
Achiko AG
Company has commenced shipping and will book first sales in May 2022Reorganized production line able to meet stronger than expected demand for Achiko AG’s innovative DNA aptamer saliva-based rapid...
Achiko AG Signs Major Marketing and Sales Agreement with World’s Largest Islamic Association for its AptameX Covid-19 Rapid Test
20 avr. 2022 07h45 HE
|
Achiko AG
Signed major deal with Pengurus Wilayah Nahdlatul Ulama DKI Jakarta, for the use of Covid-19 test AptameX in general assemblies and activities. Located primarily in Indonesia, Nahdlatul Ulama is the...
Achiko Secures up to USD$12.6 Million Equity and Debt Financing Lines with RiverFort Over Three Years
20 avr. 2022 07h30 HE
|
Achiko AG
ZURICH, Switzerland, April 20, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Achiko AG (OTCQB: ACHKF; SIX: ACHI; ISIN CH0522213468) (“Achiko”, the “Company”) announces the...
Achiko AG Production and Sales Update
03 mars 2022 07h30 HE
|
Achiko AG
Unique Chemistry with DNA Aptamers Completing Pre-Sales Validation TestingCompleting Pre-Sales Validation Testing in Indonesia ZURICH, Switzerland, March 03, 2022 (GLOBE NEWSWIRE) -- Ad...
Achiko AG Research Paper and Commercialization Update
14 févr. 2022 07h30 HE
|
Achiko AG
Calibration study results now available in draft paper on medRxiv, a preprint platform for health sciences, as “DNA Aptamer Gold Nanoparticle Colorimetric Diagnostic Test Kit of Saliva Samples for...
Achiko AG Announces Feature Article on “How We Get Back to Normal” with its AptameX™ Covid-19 Rapid Test Technology
18 janv. 2022 07h30 HE
|
Achiko AG
ZURICH, Switzerland, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Achiko AG (OTCQB: ACHKF; SIX: ACHI; ISIN CH0522213468) (“Achiko”, the “Company”) is pleased to announce a feature article in The Jakarta Post:...
Achiko AG Reports Breakthrough Calibration Results for its AptameX™ Covid-19 Rapid Test Technology
14 janv. 2022 07h30 HE
|
Achiko AG
AptameX™ Covid-19 rapid calibration successfully classified 100% of results indicatinga likely > 97% Sensitivity and > 97% Specificity result in the first-generation test kits.Results were...
Achiko AG Looks Back at Pivotal Year and Reaffirms Commitment to Provide Affordable and Accurate COVID-19 Testing Solution
23 déc. 2021 07h30 HE
|
Achiko AG
2021 Was a Pivotal Year for Achiko, Marked by Seminal Developments and ApprovalsWith AptameX™, Achiko Launched an Innovative DNA Aptamer Saliva-Based Rapid Test for Covid-19 as an Affordable and...
Achiko AG’s Shares Begin Trading on the OTCQB Market
20 déc. 2021 07h30 HE
|
Achiko AG
ZURICH, Switzerland, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Achiko AG (OTCQB: ACHKF; SIX: ACHI; ISIN CH0522213468; www.achiko.com) (“Achiko”, the “Company”), a global healthtech company which has...
Achiko’s Commercialization Update: Optimized Second-Generation Covid-19 Diagnostic Test Receives Full Product Registration Approval in Indonesia
08 déc. 2021 07h50 HE
|
Achiko AG
Second-generation of AptameX, Achiko’s innovative DNA aptamer diagnostic test for Covid-19 has received full approval in Indonesia for five yearsProduction of the second-generation AptameX kits to...